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Abstract 
Review on KIT, with data on DNA, on the protein 
encoded, and where the gene is implicated. 
Identity 
Other names: SCFR (Stem Cell Factor Receptor); 
CD117 
HGNC (Hugo): KIT 
Location: 4q12 
Local order: centromere-PDGFRA -KIT-KDR-
telomere. 
KIT (4q12) - Courtesy Mariano Rocchi 
DNA/RNA 
Description 
The KIT gene located on human chromsome 4q11 
and contains 21 exons. Exon1 encodes the initation 
codon, exon 2-9 encodes the extracellular domain, 
exon 10 the transmembrane region and exons 11-21 
the intracellular part. 
Transcription 
The 5.23 kb mRNA is alternatively spliced into two 
isoforms differing in the presence or absence of exon 
9. This splicing gives rise to KIT variants that differ
by the presence or absence of the amino acid 
sequence GNNK (denoted KIT and KITA, 
respectively). In addition there is alterative splicing 
occurring in humans, but not in mice, giving rise of 
isoforms that differ by the presence or absence of a 
serine residue in the kinase insert region. In 
postmeiotic germ cells a shorter KIT transcript is 
expressed that gives rise to a truncated version of 
KIT (tr-KIT) containing part of the kinase domain 
and the C-terminal tail. 
Protein 
Description 
976 aa; 145 kDa; type III receptor tyrosine kinase; 
glycoprotein; contains an extracellular domains with 
5 Ig-like loops, a highly hydrophobic 
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transmembrane domain (23 aa), and an intracellular 
domain with tyrosine kinase activity split by a kinase 
insert (KI) in an ATP-binding region and in the 
phosphotransferase domain. Tr-KIT does not contain 
the whole kinase domain and is therefore kinase 
inactive. 
Expression 
Hematopoietic stem cells, mast cells, melanocytes, 
germ-cell lineages and ICCs (Interstitial cells of 
Cajal).  
Expression pattern in the mouse suggest that KIT 
may play a role in tissues such as nervous system, 
placenta, heart, lung and midgestational kidneys. 
Localisation 
Plasma membrane.  
The truncated tr-KIT lacks the transmembrane 
domain and is hence not present at the plasma 
membrane. 
Function 
KIT is a cell surface receptor with tyrosine kinase 
activity; binding of ligand KITLG (also denoted 
MGF or SCF) induces receptor dimerization, 
autophosphorylation and signal transduction via 
molecules containing SH2- domains. KIT signaling 
leads to cell proliferation, survival, migration and 
differentiation. 
Homology 
with CSF-1R, PDGFRB, PDGFRA, and FLT3. 
 
Mutations 
Note 
See figures Loss-of-function mutations and Gain-of-
function mutations. 
Implicated in 
Piebaldism 
Disease 
Autosomal dominant disorder of pigmentation; loss 
of function abnormalities of the KIT gene have been 
demonstrated in 59% of the typical patients. 
Familial Gastrointestinal Stromal 
Tumors and sporadic gastrointestinal 
stromal tumors (GISTs) 
Disease 
GISTs are the most common mesenchymal tumors 
in the human digestive tract; they originate from 
KIT-expressing cells (ICCs).  
All GISTs express KIT which is frequently (80-85% 
of the cases) mutated in exon 11 encoding the 
juxtamembrane domain.  
However, also mutations in exon 9 (encoding the 
extracellular region) and 17 (encoding a region 
around the activation loop in the kinase domain) 
have been found.  
Most GIST cells produce SCF thus establishing 
autocrine stimulation. 
 
 
Loss-of-function mutations.  
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Gain-of-function mutations.  
 
Systemic Mast Cell Disease (SMCD) 
Disease 
Mast cell hyperplasia in the bone marrow, liver, 
spleen, lymph nodes, gastrointestinal tract and skin; 
gain of function mutations are detected in most 
patients.  
About 90% of patients with systemic mastocytosis 
have mutation in exon 17 in KIT, often Asp-816 is 
replaced with Val.  
In children with systemic mastocytosis the frequency 
of KIT mutations in exon 17 is lower (about 40%), 
but mutations in other KIT regions are found in 40% 
of the children, for example mutation in exon 8 and 
9 (encoding Ig-like domain 5 in the extracellular 
region of KIT). 
Prognosis 
The prognosis depends on the four clinical entities 
recognized: indolent form, form associated with 
hematologic disorder, aggressive SMCD and mast 
cell leukemia; leukemic transformation with mast 
cell involvement is characterized by rapid 
progression of disease with a survival time less than 
1 year 
Oncogenesis 
clinical features of malignant hematopoietic cell 
growth are influenced by the time, the location of c-
kit mutative events, and the number of associated 
lesions. 
Small Cell Lung cancer (SCLC) 
Disease 
KIT overexpression is found in 70% of SCLC  
patients. Co-expression ofKIT and SCF has been 
found to create an autocrine loop. The prognostic 
value of KIT expression is not clear. 
Testicular Carcinoma 
Disease 
Activating mutations in KIT exon 17 is found in 
about 25% of seminomas. Often Asp-816 is replaced 
with a Val or His residue. 
Melanoma 
Disease 
KIT is important for the development of 
melanocytes. The about 80% of melanomas contain 
BRAF mutations, but a subset contain activating 
KITmutations. Interestingly in acral melanomas 
(affecting foot soles or palms) there is a higher 
frequency of tumors with activating KIT mutations 
(20-25% of cases). Examples of KIT mutations 
found in melanoma are L576P (in exon 11) and 
K642E (in exon 13). Mutation in position 816 (in 
exon 17) has also been observed but is not so 
frequent occurring. 
Acute Myeloid Leukemia 
Disease 
KIT expression can be found in about 85% of AML 
cells. KIT activation can occur by different 
mechanisms: 1) co-expression of SCF causing an 
autocrine loop 2) activating mutations in exon 17 
affecting Asp-816 or Asn-822. Interestingly, KIT 
mutations occurs primarily in a subset of leukemias 
containing inv(16) or t(8;21), so-called core factor 
binding AML. Apart from exon 17 mutations, also 
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internal tandem duplications in exon 11 have been 
described. 
Prognosis 
Presence of D816V mutation in KIT is a poor 
prognostic factor. 
To be noted 
Note 
Loss of expression of KIT appears to be associated 
with progression of some tumors (melanoma) and 
autocrine/paracrine stimulation of the KIT/KITLG 
system may participate in human solid tumors such 
as lung, breast, testicular and gynecological 
malignancies. 
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